Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. - Wikidata - awgldk - TriplyDB

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

http://www.wikidata.org/entity/Q36759111

about

Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma.The safety of nivolumab for the treatment of metastatic melanoma.The safety of anti PD-1 therapeutics for the treatment of melanoma.Nivolumab in melanoma.Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.Myeloid-Derived Suppressor Cells.Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.Predictors of responses to immune checkpoint blockade in advanced melanoma Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.Trial watch: Immune checkpoint blockers for cancer therapy.Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.Cancer immunotherapy: A need for peripheral immunodynamic monitoring.Thyroid dysfunctions secondary to cancer immunotherapy.Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.Myeloid-derived suppressor cells coming of age.Cancer vaccine: learning lessons from immune checkpoint inhibitors.LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance Biomarkers for Immune Checkpoint Inhibitors in Melanoma

P2860

Q30235360-DF0162B0-BA6E-43C3-BB02-E723338A5BAB Q37718449-15C66879-8A1F-4C45-9C32-C983EEDA87F5 Q38662469-CED8BA86-BF7F-46E2-94E2-803569FFABFD Q38979801-04B29E6E-5159-4246-BAA8-A00C6BFD37BA Q38989508-311D3E43-A204-40F5-81BA-FAEF71F08292 Q39009781-9ECE4808-F1E2-4370-8317-77BC6939D8AA Q39103948-AA39E5CA-F1EE-4FBA-A041-C6F6B1CBEB32 Q40385399-87B17715-5A90-470E-A3EB-730D81972B43 Q41520240-07A4920E-241F-4E4C-B820-A917B312ED06 Q41634246-79D79CB0-6E07-47A0-B98D-91160CB45D2E Q41701241-BA0EC58F-8A38-4EBE-B310-AB59361F29E3 Q41831841-5BBE47BD-F701-43B7-AECF-609BC0AF4379 Q42369277-35A096AC-B3DF-441D-9691-84D707F00CDF Q42371630-ECC943B4-9E4F-4745-AB4B-D20AB49C5C00 Q45070125-7256A331-C6B3-4DFC-BE11-1EDF7DC6A9EA Q47101155-83041140-1B8D-44ED-9E9B-2BB8C0CE506F Q47119885-ACB61CD4-CFCC-40A4-902D-294001AAAD89 Q47144801-5DF2DABE-4E76-476D-B92E-61196D50044E Q47219905-13B8F1C6-C6BF-4261-8F50-14DC8921C212 Q47393365-BF90427D-8F41-4D44-A9CF-0CE49EBCC443 Q47404669-43214D4B-00E3-4E04-B707-BD5B61EDCE2A Q47561904-5048E9C7-F73E-453C-B01A-88CF575F6156 Q47565857-146BAA9E-DCC2-4908-A915-184618ADA6BA Q47705923-133BC3DB-24B7-4074-936A-553115B8C03E Q48215791-F2C35FC2-B681-4A3E-96B1-8378F51EF52F Q49260236-16ED42B1-F714-45B7-8D97-56771F29F610 Q50034376-B589E1A3-BAA2-4DEA-B745-2D0E108F6699 Q50213474-DC715604-1879-4FBD-A78D-60B297A846AE Q55401509-CE867E8D-511C-4693-A001-2CD00451C21C Q56891609-5B28BAB1-320E-4429-9452-26C90F0B3366 Q57138311-74AC7470-7103-462C-A87A-B84E96375D25 Q57167969-5A2FBF34-4339-4E7B-95B8-81C4E1993741 Q57175477-9B3BBF0B-8A1B-4929-93C7-B7E8A58EC739

P2860

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.

http://www.wikidata.org/entity/Q36759111

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Phase I/II Study of Metastatic ...... d Progressed after Ipilimumab.

@ast

Phase I/II Study of Metastatic ...... d Progressed after Ipilimumab.

@en

type

label

Phase I/II Study of Metastatic ...... d Progressed after Ipilimumab.

@ast

Phase I/II Study of Metastatic ...... d Progressed after Ipilimumab.

@en

prefLabel

Phase I/II Study of Metastatic ...... d Progressed after Ipilimumab.

@ast

Phase I/II Study of Metastatic ...... d Progressed after Ipilimumab.

@en

P1433

Q36759111-080DB40C-99AC-4ABC-9884-AAFDFBF85FB0

P1476

Q36759111-086709A6-DE49-4A82-A09E-AC3BA05650A0

P2093

Q36759111-02AD227C-2CBC-41C9-A28A-8319C62050DE

Q36759111-3C4D5FEF-001C-46BD-ADE2-5FBE3B20C990

Q36759111-5B05BBBB-AB94-4D7C-BF91-39279A2F8313

Q36759111-6081BD2D-1E23-4819-AE1A-15A0A71EE021

Q36759111-73FBC31F-09D6-4603-B0D3-E90099E60104

Q36759111-75CE4E02-71D1-4BDA-81BC-A74F3F738CFA

Q36759111-86C42D92-669F-4A42-8B8A-591BDCBEB54F

Q36759111-944CEA02-2D3A-4B6C-9A83-BD1AE1E36C12

Q36759111-B7218169-CD98-4537-B8A8-D5BF2D10C097

Q36759111-BF709048-9A98-42DC-816C-21E0FFDDE128

P2860

Q36759111-0A7C2683-68C4-439A-AF6E-A1271DD865D4

Q36759111-18D5E96F-3B4F-4422-AEE9-EAEC0965C85C

Q36759111-190EE928-C1E9-4E69-90E9-879AF4649A1B

Q36759111-1B221FC3-E118-4034-98EC-6AF11AA41AB4

Q36759111-21330B76-4AC2-469C-9AF5-C25BDFBCF807

Q36759111-2166DE71-88B5-4BE7-8FD4-168D2D1E9B52

Q36759111-2FBE6078-9DB9-431C-9C04-BC8C54C5CF85

Q36759111-33B045D7-14B3-4142-BBB4-ABDFD803103F

Q36759111-359F6B6B-9441-4CF5-BA80-441D6D9270E8

Q36759111-37EA1923-4F7C-4412-B047-769696583269

P304

Q36759111-1315D498-864F-422C-83C2-86D00A8F7360

P31

Q36759111-29B262DC-AB3C-4047-AA42-67B5B8C2282E

P356

Q36759111-AA2977EF-C06C-4AC1-ABF0-28DA70AA27F8

P433

Q36759111-8C5D3809-E8D9-432A-B73E-61DD2C3A22AE

P478

Q36759111-BB9C18E6-4C8F-4AC8-A8ED-290BE710BEF9

P50

Q36759111-CDBEFA6F-107C-41F8-9047-1CA1000A3376

P577

Q36759111-BA5D55FD-BE15-491A-B831-CD038C1F73CB

P698

Q36759111-CD885FA5-E906-4D5E-85D7-437128A79921

P921

Q36759111-12F4CC07-2AB3-41B1-BCA9-B9C1D4798266

P932

Q36759111-8C238357-74F2-4063-9EAC-15B3C20D077F

P356

2326-6066.CIR-15-0193

P1433

Cancer immunology research

P1476

Phase I/II Study of Metastatic ...... ad Progressed after Ipilimumab

@en

P2093

Alberto J Martinez

http://www.w3.org/2001/XMLSchema#string

Allison Richards

http://www.w3.org/2001/XMLSchema#string

Bin Yu

http://www.w3.org/2001/XMLSchema#string

Geoffrey Gibney

http://www.w3.org/2001/XMLSchema#string

Heather Cronin

http://www.w3.org/2001/XMLSchema#string

Jodie Kroeger

http://www.w3.org/2001/XMLSchema#string

Lori McCormick

http://www.w3.org/2001/XMLSchema#string

Michael Schell

http://www.w3.org/2001/XMLSchema#string

Pingyan Cheng

http://www.w3.org/2001/XMLSchema#string

Ragini Kudchadkar

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Coordinated regulation of myeloid cells by tumours

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Nivolumab in previously untreated melanoma without BRAF mutation

P304

345-353

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-15-0193

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey S Weber

P577

2016-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26873574

http://www.w3.org/2001/XMLSchema#string

P921

P932

4818672

http://www.w3.org/2001/XMLSchema#string